What is

an HMO

GP fundholding

outcomes analysis?

LIFs Annual Meeting June 5th 1998
09.00 Hörsalen, Göta Arkhuset, Medborgarplatsen 25, Stockholm

Speakers

Claes Handin, Chairman of the Board of Directors of LIF and Managing Director of SmithKline Beecham Nordic Operations.

Larry C Goodnight, RPh. is the Director, Managed Care Pharmacy at the Scott & White Health Plan located in Temple, TX. Primary responsibilities include overall fiscal control and financial management for the Scott & White Health Plan Pharmacies. He is directly responsible for negotiation and implementation of all pharmaceutical contracts for the Scott & White Health Plan and Scott & White Prescription Services. Other responsibilities include formulary development and management, data management, Physician prescribing patterns, DUR and DUE. Mr. Goodnight received his BS in pharmacy from the University of Texas College of Pharmacy.

Darrin Baines, BA (Hons), MSc, is a Senior Lecturer in Health Economics at the University of Birmingham, Health Services Management Centre. Darrin has a degree in economics at the University of York. He spent a year studying for an MSc in Health Economics at York University and three years studying for a PhD in Health Economics, Department of Economics, University of Nottingham. His PhD was sponsored by the NHS health authority, Lincolnshire Health. The topic of his PhD thesis was the effects of the NHS reforms (particularly GP fundholding) on prescribing and general practice in Lincolnshire. Darrin's PhD research led to the production of several papers, published jointly with his supervisors and other members of academic staff within Nottingham University.



Dr Flemming Ørnskov completed his MD at the University of Copenhagen, Denmark. He also holds an MBA from INSEAD, France and an MPH in Health Policy and Health Care Management from Harvard University. He trained in pediatrics at the University Hospital of Copenhagen and was an adjunct associate professor at the University of Copenhagen Medical School in clinical decision sciences and medical ethics. He joined Merck & Co, Inc in 1994 in Outcomes Research and is now Director, NeuroScience Group. He has written multiple peer reviewed articles, book chapters and monographs.

Programme

09.00 – 09.30	Coffee
09.30 – 09.45	Introduction, Claes Handin, Chairman, LIFs Board of Directors
09.45 – 10.30	Partnership opportunities with the pharmaceutical industry – an HMO perspective. Larry C Goodnight, Scott & White Health Plan
10.30 – 11.15	The effects of the GP fundholding scheme on prescribing in UK general practice. Darrin Baines, University of Birmingham
11.15 – 11.30	Pause
11.30 – 12.15	Outcomes analysis – a challenge for the pharmaceutical industry. Flemming Ørnskov, Merck & Co Inc
12.15 – 13.00	Questions and comments
13.00 – 14.00	Lunch

Läkemedelsindustriföreningen

The Swedish Association of the Pharmaceutical Industry

Medborgarplatsen 25 plan 8 Box 17608 118 92 Stockholm
Tel 46 (8) - 462 37 00 Fax 46 (8) - 462 02 92